How FGF Storage, Stability and Handling Appear in the Research

What This Page Covers — and How to Read the Evidence

Fibroblast growth factors (FGFs) are a large family of signalling proteins studied across skeletal biology, metabolism, wound repair and development. Because they are proteins rather than short synthetic peptides, questions about their handling — refrigeration, freezing, shelf life, travel, visible degradation — sit at the intersection of two very different bodies of information. This page keeps those two bodies separate throughout.

• FGF-specific findings. Statements drawn from published FGF papers. Each one carries its PubMed link in the same sentence, so the source of every claim is visible where the claim is made.
• General lyophilized-protein principles. Broad points taught in protein biochemistry about freeze-dried versus dissolved proteins. These are explicitly labelled as general and are not reported by any FGF study cited on this page.

This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about a specific compound, product or health decision. Nothing below is a handling instruction, a storage protocol, or a recommendation of any temperature, container, duration or quantity.

Why FGF Stability Is a Research Question at All

The FGF family is not one molecule. A 2024 review in Military Medical Research examined signalling pathways in age-related orthopedic diseases with a focus on the fibroblast growth factor family, and described multiple family members acting through distinct receptor pathways in bone and cartilage biology (https://pubmed.ncbi.nlm.nih.gov/38902808/). A separate 2022 review characterised FGF21 as a regulator of glucose and lipid metabolism and whole-body energy balance, a role quite unlike the local tissue-repair functions attributed to other family members (https://pubmed.ncbi.nlm.nih.gov/35413740/). Receptor biology adds further divergence: a 2015 review of FGFR3 biology and skeletal disease described how signalling through a single receptor shapes skeletal development and disease (https://pubmed.ncbi.nlm.nih.gov/26075305/).

The practical consequence for anyone reading storage claims is that "FGF" is not a single storage case. Findings about FGF-2 do not automatically transfer to FGF-18, FGF-21 or FGF-10, and none of the reviews above addressed container temperature or shelf life at all.

"Stability" Means Several Different Things in FGF Papers

Search results and abstracts that pair "FGF" with "stability" often describe something other than storage stability. Three distinct usages appear in the cited literature.

1. Thermal and structural stability of the protein itself

This is the usage closest to a storage question. A 2025 paper in Cellular and Molecular Life Sciences reported that increased thermal stability of FGF10 led to ectopic signalling during development, meaning that altering how resistant the protein was to thermal destabilisation changed where and how signalling occurred (https://pubmed.ncbi.nlm.nih.gov/40257501/). Researchers in a 2023 Computational and Structural Biotechnology Journal report described a computer-assisted approach to stabilizing fibroblast growth factor FGF-18, an engineering effort undertaken because the native protein's stability was a limiting property (https://pubmed.ncbi.nlm.nih.gov/37920818/). Taken together, those two papers indicate that intrinsic stability is variable across FGFs and can be deliberately altered (https://pubmed.ncbi.nlm.nih.gov/40257501/).

2. Stability of something else in the biological system

A 2024 study in Acta Biochimica et Biophysica Sinica reported that inducible Fgf13 ablation alleviated cardiac fibrosis via regulation of microtubule stability — here "stability" referred to intracellular cytoskeletal structures, not to the growth factor's shelf life (https://pubmed.ncbi.nlm.nih.gov/38818580/).

3. Mechanical stability in a tissue or device context

A 2017 study in Clinical Oral Implants Research reported that FGF-2 promoted initial osseointegration and enhanced the stability of implants with low primary stability — a measure of implant fixation, again unrelated to protein storage (https://pubmed.ncbi.nlm.nih.gov/26919334/).

Conflating these three senses of the word is the single most common error in secondary write-ups about FGF storage.

Refrigeration: Lyophilized Versus Reconstituted Material

General principle, not FGF-specific: in protein biochemistry it is widely taught that removing water by lyophilisation slows the chemical reactions that degrade proteins — hydrolysis, deamidation and aggregation among them — so freeze-dried material is generally treated as more robust than the same protein in solution, and solutions are generally treated as the more fragile state. That distinction is a general principle of protein handling. No FGF paper cited on this page compared a refrigerated lyophilized FGF preparation with a refrigerated reconstituted one, reported a temperature, or reported a holding time.

What the FGF literature does supply is indirect support for the idea that the dissolved protein is the vulnerable state. Multiple groups built delivery systems whose stated purpose was to carry and protect FGF-2 rather than leave it free in solution: researchers prepared FGF-2-incorporated carboxymethyl chitosan nanoparticles and evaluated them in vitro (https://pubmed.ncbi.nlm.nih.gov/28732849/), and a 2020 study described a chitin degradation enzyme-responsive system for controlled release of fibroblast growth factor-2 (https://pubmed.ncbi.nlm.nih.gov/31492610/). The existence of that engineering effort is evidence about formulation strategy; it is not a refrigeration guideline.

Shelf Life and Expiry Dating

Expiry dating is a regulatory and manufacturing concept rather than a finding from the biology literature. For an approved biologic product, the expiry date is set by the manufacturer on the basis of formal stability programmes conducted on that exact formulation, container and closure; for research-use-only (RUO) material, documentation typically accompanies the specific lot. Those are regulatory and manufacturing facts, not study findings, and none of the FGF papers cited here reported a shelf life, a dating period or a stability-indicating assay result.

The FGF-specific literature does explain why dating would be formulation-specific rather than family-wide: because stability differs between family members and can be altered by protein engineering, as researchers reported for FGF-18 (https://pubmed.ncbi.nlm.nih.gov/37920818/) and for FGF10 (https://pubmed.ncbi.nlm.nih.gov/40257501/), a number generated for one preparation cannot be assumed to describe another.

Room Temperature and Travel

General principle, not FGF-specific: proteins held above their intended storage temperature are generally understood to degrade faster, with rates rising as temperature rises, and excursions during shipping or transport are for that reason a standard concern in cold-chain logistics for biologics. That framework is general; it is not an FGF finding.

The closest FGF-specific anchor is thermal: the 2025 FGF10 study reported that the protein's thermal stability was a determinant of its signalling behaviour, with an increase in thermal stability producing ectopic signalling during development (https://pubmed.ncbi.nlm.nih.gov/40257501/). That result concerned engineered variants in a developmental model, not vials in transit, and cannot be converted into a permitted time at room temperature. No cited paper reported how long any FGF preparation retained activity at ambient temperature.

Freezing and Freeze–Thaw

General principle, not FGF-specific: freezing is widely used to slow degradation of protein solutions, while repeated freeze–thaw cycling is generally described as a stress that can promote aggregation and loss of activity; single-use aliquoting exists in laboratories precisely to limit that cycling. Again, this is general protein handling, not an FGF result.

No study in this page's citation set reported freeze–thaw data for any FGF. What the literature instead shows is a body of work on protecting the protein through its carrier: a 2023 Macromolecular Bioscience study described coacervate-filled lipid vesicles for protein delivery (https://pubmed.ncbi.nlm.nih.gov/36749955/), and a 2017 Advanced Healthcare Materials study reported controlling the release of small, bioactive proteins via dual mechanisms with therapeutic potential (https://pubmed.ncbi.nlm.nih.gov/29024487/). Those reports describe delivery engineering, not freezer policy.

Signs of Degradation: What Studies Report

Readers looking for a checklist of visual cues — cloudiness, clumping, discoloration, cake collapse in a lyophilized vial — will not find one in the cited FGF literature. No study on this page reported visual degradation criteria for an FGF preparation. Visual inspection cues are general pharmaceutical-handling lore, not FGF findings, and the general framework holds that a protein can lose biological activity with no visible change at all, which is why laboratories rely on assays rather than appearance.

The FGF-specific literature describes degradation in functional terms instead. Researchers reported that shifting FGF10's thermal stability changed signalling outcomes during development, indicating that structural state and biological behaviour are coupled (https://pubmed.ncbi.nlm.nih.gov/40257501/), and the FGF-18 stabilization study framed limited native stability as the problem that computational redesign was intended to solve (https://pubmed.ncbi.nlm.nih.gov/37920818/). Adverse events in the human sense were not the subject of either report.

Why Formulation, Not Storage, Dominates the FGF Literature

Across the cited papers, the recurring theme is that investigators addressed FGF fragility by changing the material around the protein rather than by changing a storage temperature. Researchers prepared and evaluated FGF-2-incorporated carboxymethyl chitosan nanoparticles in vitro (https://pubmed.ncbi.nlm.nih.gov/28732849/); a separate group reported an enzyme-responsive system releasing FGF-2 upon chitin degradation (https://pubmed.ncbi.nlm.nih.gov/31492610/); vesicle-based carriers were described for protein delivery generally (https://pubmed.ncbi.nlm.nih.gov/36749955/); and dual-mechanism systems were reported for controlling release of small bioactive proteins (https://pubmed.ncbi.nlm.nih.gov/29024487/). In parallel, protein-engineering work sought to raise intrinsic stability directly, as in the FGF-18 redesign study (https://pubmed.ncbi.nlm.nih.gov/37920818/).

One further caution about interpreting FGF-2 findings: signalling by basic FGF is context-dependent, and a 2017 Oncotarget study reported that metformin reversed bFGF-induced epithelial-mesenchymal transition in hepatocellular carcinoma cells (https://pubmed.ncbi.nlm.nih.gov/29262637/). Papers of that kind are about biology, not handling, and are sometimes miscited in storage discussions.

What the Cited Literature Does Not Establish

• No cited FGF paper reported a storage temperature, a refrigerated holding time or a shelf-life period.
• No cited FGF paper compared lyophilized with reconstituted material under matched conditions.
• No cited FGF paper reported freeze–thaw tolerance, travel excursion limits or visual degradation criteria.
• Findings about one family member, such as the FGF10 thermal-stability report (https://pubmed.ncbi.nlm.nih.gov/40257501/), were not shown to describe other FGFs.

Where this page states a general protein-handling principle, that statement is labelled as general and is not attributed to any study. Where it states an FGF finding, the PubMed link appears in the same sentence. Product-specific storage information for any approved or research-use-only preparation comes from that product's own documentation and from a licensed clinician or qualified investigator, not from the biology papers summarised here.

References

• Role of signaling pathways in age-related orthopedic diseases: focus on the fibroblast growth factor family (Military Medical Research, 2024)
• Increased thermal stability of FGF10 leads to ectopic signaling during development (Cellular and Molecular Life Sciences, 2025)
• FGF21: A Novel Regulator of Glucose and Lipid Metabolism and Whole-Body Energy Balance (Hormone and Metabolic Research, 2022)
• Preparation and in vitro evaluation of FGF-2 incorporated carboxymethyl chitosan nanoparticles (Carbohydrate Polymers, 2017)
• Chitin degradation enzyme-responsive system for controlled release of fibroblast growth factor-2 (Journal of Bioscience and Bioengineering, 2020)
• Coacervate-Filled Lipid Vesicles for Protein Delivery (Macromolecular Bioscience, 2023)
• Computer-assisted stabilization of fibroblast growth factor FGF-18 (Computational and Structural Biotechnology Journal, 2023)
• Inducible Fgf13 ablation alleviates cardiac fibrosis via regulation of microtubule stability (Acta Biochimica et Biophysica Sinica, 2024)
• FGFR3 biology and skeletal disease (Connective Tissue Research, 2015)
• Metformin reverses bFGF-induced epithelial-mesenchymal transition in HCC cells (Oncotarget, 2017)
• FGF-2 promotes initial osseointegration and enhances stability of implants with low primary stability (Clinical Oral Implants Research, 2017)
• Controlling the Release of Small, Bioactive Proteins via Dual Mechanisms with Therapeutic Potential (Advanced Healthcare Materials, 2017)